Viracta Therapeutics Inc (VIRX) - News Archive

The landscape of clinical oncology is ever-evolving, marked by innovations as well as setbacks. A recent announcement from Viracta Therapeutics, a pioneering entity in precision oncology targeting virus-associated cance...

In a significant strategic pivot aimed at sharpening its developmental focus, Viracta Therapeutics has announced a realignment of resources that will prioritize its promising Nana-val program for patients grappling with...

Viracta Therapeutics has recently announced exciting advancements in its clinical development, revealing positive outcomes from the Phase 2 NAVAL-1 trial focusing on relapsed or refractory Epstein-Barr virus (EBV)-posit...

Advancing Precision Oncology: Viracta Therapeutics’ Strategic Developments and Leadership Appointments In a noteworthy series of corporate and clinical advancements, Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical...

In a groundbreaking development, Viracta Therapeutics has announced the positive topline results from Stage 1 of the NAVAL-1 Trial. This trial evaluated the efficacy and safety of Nana-val (nanatinostat in combination w...

In this article, we will discuss the recent achievement of Viracta Therapeutics, a leading biopharmaceutical company specializing in targeted treatments for cancer. Specifically, we will explore their progress in comple...

Viracta Therapeutics: Advancing a Promising Treatment for Relapsed or Refractory EBV Peripheral T-cell Lymphoma Viracta Therapeutics, a leading clinical-stage biotechnology company, has provided an update on the progres...

In a significant breakthrough for the field of cancer therapeutics, Viracta Therapeutics has recently announced that the United States Food and Drug Administration (FDA) has granted the company Orphan Drug Designation f...

Viracta Therapeutics Announces Promising Interim Data for Nana-val in Treating Epstein-Barr Virus-Positive Solid TumorsViracta Therapeutics, a leading biotechnology company focused on innovative treatments for viral-ass...